Close Menu

SBIR grant

The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.

The company aims to commercialize the platform and related services by late 2018.

The SBIR Phase 1 award will go toward developing a test using immuno-PCR technology to detect toxins in medical marijuana. 

The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.

The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.

The funding will go towards developing the PathMap companion diagnostic technology, based on the firm's SnapPath platform. 

Proposed increases to small business programs touch off fight between business and research groups, ScienceInsider reports.

The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.

The firm said the method could lead to more studies on the genetic determinants of disease for people of mixed or non-European ethnic backgrounds.

The companies are combining GMSbiotech's proprietary microarray platform with soluble human leukocyte antigen proteins produced by Pure Protein.

Pages

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.